Hyperthermia for locally advanced breast cancer.
Hyperthermia (HT) has a proven benefit for treating superficial malignancies, particularly chest wall recurrences of breast cancer. There has been less research utilising HT in patients with locally advanced breast cancer (LABC), but available data are promising. HT has been combined with chemotherapy and/or radiotherapy in the neoadjuvant, definitive and adjuvant setting, albeit in series with small numbers of patients. There is only one phase III trial that examines hyperthermia in LABC, also with relatively small numbers of patients. The goal of this review is to highlight important research utilising HT in patients with LABC as well as to suggest future directions for its use.
Zagar
Timothy M
TM
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Oleson
James R
JR
Vujaskovic
Zeljko
Z
Dewhirst
Mark W
MW
Craciunescu
Oana I
OI
Blackwell
Kimberly L
KL
Prosnitz
Leonard R
LR
Jones
Ellen L
EL
D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced